Comparative study of the hypoglycaemic and antilipolytic effects of four antidiabetic agents administered i.v.
The effects of i.v. administration of equipotent doses of glycodiazine, glibenclamide, desaglybuzol and glydiazinamide on the level of blood sugar and plasma free fatty acids (FFA) have been assessed in 30 diabetic patients and 24 healthy controls. Glibenclamide proved to have the most potent hypoglycaemic effect in diabetics. The decrease in blood sugar level was less sustained after glycodiazine as compared with the other three drugs. This is due mostly to differences in dynamics of insulin secretion. Glibenclamide also proved to have pronounced and most sustained antilipolytic action. In contrast, desaglybuzol, like phenformin (a biguanide), failed to cause a drop in the level of plasma FFA and hence can be recommended in obese diabetic patients.
D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D003920:Diabetes Mellitus / Q000097:blood; D005230:Fatty Acids, Nonesterified / Q000097:blood*; D005260:Female; D005913:Glipizide / Q000008:administration & dosage / Q000494:pharmacology; D005905:Glyburide / Q000008:administration & dosage / Q000494:pharmacology; D006801:Humans; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007275:Injections, Intravenous; D008297:Male; D008875:Middle Aged; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D013830:Thiadiazoles / Q000008:administration & dosage / Q000494:pharmacology
D001786:Blood Glucose; D005230:Fatty Acids, Nonesterified; D007004:Hypoglycemic Agents; D013449:Sulfonamides; D013830:Thiadiazoles; D005905:Glyburide; D005913:Glipizide